Capillary Biomedical takes aim at ‘the Achilles heel of diabetes’

Major players in the medical device realm are in a heated race to develop the first artificial pancreas to help patients with diabetes manage the chronic condition. Just last year,  Medtronic (NYSE:MDT) won FDA approval for its MiniMed 670G hybrid-closed loop system.

But while companies compete for the top spot in developing what could be a fundamental change to diabetes management, Paul Strasma and Dr. Jeffrey Joseph of Capillary Biomedicalare focused on optimizing one particularly important part of the system – insulin infusion.

Get the full story at our sister site, Drug Delivery Business News.

The post Capillary Biomedical takes aim at ‘the Achilles heel of diabetes’ appeared first on MassDevice.

from MassDevice http://ift.tt/2uy7vmn